Unknown

Dataset Information

0

Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development.


ABSTRACT: Programmed cell death protein 1 (PD-1) plays a significant role in suppressing antitumor immune responses. Cancer treatment with immune checkpoint inhibitors (ICIs) targeting PD-1 has been approved to treat numerous cancers and is the backbone of cancer immunotherapy. Anti-PD-1 molecule is necessary for next-generation cancer immunotherapy to further improve clinical efficacy and safety as well as integrate into novel treatment combinations or platforms. We developed a highly efficient hybridoma generation and screening strategy to generate high-potency chimeric anti-PD-1 molecules. Using this strategy, we successfully generated several mouse hybridoma and mouse/human chimeric clones that produced high-affinity antibodies against human PD-1 with high-quality in vitro PD-1/PD-L1 binding blockade and T cell activation activities. The lead chimeric prototypes exhibited overall in vitro performance comparable to commercially available anti-PD-1 antibodies and could be qualified as promising therapeutic candidates for further development toward immuno-oncology applications.

SUBMITTER: Phakham T 

PROVIDER: S-EPMC9588028 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development.

Phakham Tanapati T   Boonkrai Chatikorn C   Wongtangprasert Tossapon T   Audomsun Thittaya T   Attakitbancha Chadaporn C   Saelao Pijitra P   Muanwien Phijitra P   Sooksai Sarintip S   Hirankarn Nattiya N   Pisitkun Trairak T  

Scientific reports 20221022 1


Programmed cell death protein 1 (PD-1) plays a significant role in suppressing antitumor immune responses. Cancer treatment with immune checkpoint inhibitors (ICIs) targeting PD-1 has been approved to treat numerous cancers and is the backbone of cancer immunotherapy. Anti-PD-1 molecule is necessary for next-generation cancer immunotherapy to further improve clinical efficacy and safety as well as integrate into novel treatment combinations or platforms. We developed a highly efficient hybridoma  ...[more]

Similar Datasets

| S-EPMC6492981 | biostudies-literature
| S-EPMC7972868 | biostudies-literature
2024-03-18 | PXD043489 | Pride
| S-EPMC10533561 | biostudies-literature
| S-EPMC4622687 | biostudies-literature
| S-EPMC5223223 | biostudies-literature
| S-EPMC9496473 | biostudies-literature
| S-EPMC5925824 | biostudies-literature
| S-EPMC8504763 | biostudies-literature
| S-EPMC11632933 | biostudies-literature